<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Neuromuscular Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Neuromuscular Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Нервно-мышечные болезни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-8721</issn><issn publication-format="electronic">2413-0443</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32</article-id><article-id pub-id-type="doi">10.17650/2222-8721-2014-0-4-12-19</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>LECTURES AND REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЛЕКЦИИ И ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine</article-title><trans-title-group xml:lang="ru"><trans-title>Ацетил-L-карнитин при дистимических расстройствах в пожилом возрасте: двойное слепое, мультицентровое, контролируемое рандомизированное исследование в сравнении с флуоксетином</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bersania</surname><given-names>Giuseppe</given-names></name><address><country country="RU">Russian Federation</country></address><email>giuseppe.bersani@uniroma1.it</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Meco</surname><given-names>Giuseppe</given-names></name><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Denaro</surname><given-names>Alessandro</given-names></name><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Liberati</surname><given-names>Damien</given-names></name><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Colletti</surname><given-names>Chiara</given-names></name><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Nicolai</surname><given-names>Raffaella</given-names></name><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name><surname>Bersania</surname><given-names>Francesco Saverio</given-names></name><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Koverech</surname><given-names>Aleardo</given-names></name><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff id="aff1"><institution>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Italy</institution></aff><aff id="aff2"><institution>Department of Neurology and Psychiatry, Sapienza University of Rome, Italy</institution></aff><aff id="aff3"><institution>Department of Neuromotor Rehabilitation, Istituto Chirurgico Ortopedico Traumatologico (ICOT), Latina, Italy</institution></aff><aff id="aff4"><institution>Corporate R&amp;D Sigma-Tau S.p.A., Pomezia, Italy</institution></aff><aff id="aff5"><institution>Carnitine Development Dept., Sigma-Tau S.p.A., Pomezia, Italy</institution></aff><pub-date date-type="pub" iso-8601-date="2014-12-19" publication-format="electronic"><day>19</day><month>12</month><year>2014</year></pub-date><volume>4</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>12</fpage><lpage>19</lpage><history><date date-type="received" iso-8601-date="2015-02-19"><day>19</day><month>02</month><year>2015</year></date><date date-type="accepted" iso-8601-date="2015-02-19"><day>19</day><month>02</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Bersania G., Meco G., Denaro A., Liberati D., Colletti C., Nicolai R., Bersania F., Koverech A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, Bersania G., Meco G., Denaro A., Liberati D., Colletti C., Nicolai R., Bersania F., Koverech A.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Bersania G., Meco G., Denaro A., Liberati D., Colletti C., Nicolai R., Bersania F., Koverech A.</copyright-holder><copyright-holder xml:lang="ru">Bersania G., Meco G., Denaro A., Liberati D., Colletti C., Nicolai R., Bersania F., Koverech A.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://nmb.abvpress.ru/jour/article/view/32">https://nmb.abvpress.ru/jour/article/view/32</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> L-Acetylcarnitine (LAC), the acetyl ester of carnitine naturally present in the central nervous system and involved in several neural pathways, has been demonstrated to be active in various animal experimental models resembling some features of human depression. The aim of the study is to verify whether LAC can have an antidepressant action in a population of elderly patients with dysthymic disorder in comparison with a traditional antidepressant such as fluoxetine.</p><p><bold>Methods</bold>. Multicentric, double-blind, double-dummy, controlled, randomized study based on a observation period of 7 weeks. 80 patients with DSM-IV diagnosis of dysthymic disorder were enrolled in the study and subdivided into 2 groups. Group A patients received LAC plus placebo; group B patients received fluoxetine 20 mg/die plus placebo. Clinical assessment was performed through several psychometric scales at 6 different moments.</p><p><bold>Results</bold>. Group A patients showed a statistically significant improvement in the following scales: HAM-D, HAM-A, BDI and Touluse–Pieron Test. Comparison between the two groups, A and B, generally showed very similar clinical progression.</p><p><bold>Discussion.</bold> The results obtained with LAC and fluoxetine were equivalent. As the subjects in this study were of senile age, it is possible to hypothesize that the LAC positive effect on mood could be associated with improvement in subjective cognitive symptomatology. The difference in the latency time of clinical response (1 week of LAC treatment, compared with the 2 weeks' latency time with fluoxetine) suggests the existence of different mechanisms of action possibly in relation to the activation of rapid support processes of neuronal activity.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>L-Acetylcarnitine</kwd><kwd>depression</kwd><kwd>fluoxetine</kwd><kwd>dysthymic disorder</kwd><kwd>psychometric scales</kwd><kwd>cognitive symptomatology</kwd><kwd>hippocampus</kwd><kwd>antidepressants</kwd><kwd>neurotrophic factors</kwd><kwd>dementia</kwd><kwd>stress</kwd><kwd>neurogenesis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ацетил-L-карнитин</kwd><kwd>депрессия</kwd><kwd>флуоксетин</kwd><kwd>дистимическое расстройство</kwd><kwd>психометрические шкалы</kwd><kwd>когнитивные симптомы</kwd><kwd>гиппокамп</kwd><kwd>антидепрессанты</kwd><kwd>нейротрофические факторы</kwd><kwd>деменция</kwd><kwd>стресс</kwd><kwd>нейрогенез</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Angelucci L., Ramacci M.T. Hypothalamopituitary adrenocortical function in aging: effects of acetyl-L-carnitine. In: Stress, immunity and ageing. A role for acetyl-Lcarnitine, 1989.</mixed-citation><mixed-citation xml:lang="ru">Angelucci L., Ramacci M.T. Hypothalamopituitary adrenocortical function in aging: effects of acetyl-L-carnitine. In: Stress, immunity and ageing. A role for acetyl-Lcarnitine, 1989.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Bahring R., Standhardt H., Arrigoni Martelli E., Grantyn R. GABAactivated chloride currents of Postnatal mouse retinal ganglion cells are blocked by Acetylcholine and Acetylcarnitine: how specific are ion channel in immature neurons. Eur J Neurosci 1994;6,1089–9 9.</mixed-citation><mixed-citation xml:lang="ru">Bahring R., Standhardt H., Arrigoni Martelli E., Grantyn R. GABAactivated chloride currents of Postnatal mouse retinal ganglion cells are blocked by Acetylcholine and Acetylcarnitine: how specific are ion channel in immature neurons. Eur J Neurosci 1994;6,1089–9 9.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Bella R., Biondi R., Raffaele R., Pennisi G. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res 1990;10(6):355–60.</mixed-citation><mixed-citation xml:lang="ru">Bella R., Biondi R., Raffaele R., Pennisi G. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res 1990;10(6):355–60.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Chiechio S., Copani A., DePetris L. et al. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NFkappa B pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of L-acetylcarnitine. Mol Pain 2006;2:20–8.</mixed-citation><mixed-citation xml:lang="ru">Chiechio S., Copani A., DePetris L. et al. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NFkappa B pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of L-acetylcarnitine. Mol Pain 2006;2:20–8.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Chiechio S., Copani A., Zammataro M. et al. Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol Sci 2010;31(4):153–60.</mixed-citation><mixed-citation xml:lang="ru">Chiechio S., Copani A., Zammataro M. et al. Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol Sci 2010;31(4):153–60.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Fulgente T., Onofrj M., Del Re M.L. et al. L-Acetylcarnitine treatment of senile depression. Clin Trial J 1990;27(3):155–63.</mixed-citation><mixed-citation xml:lang="ru">Fulgente T., Onofrj M., Del Re M.L. et al. L-Acetylcarnitine treatment of senile depression. Clin Trial J 1990;27(3):155–63.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Garzya G., Corallo D., Fiore A. et al. Evaluation of the effects of L-Acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990;16(2):101–6.</mixed-citation><mixed-citation xml:lang="ru">Garzya G., Corallo D., Fiore A. et al. Evaluation of the effects of L-Acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990;16(2):101–6.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Harsing L.G., Sershen H., Toth E. et al. Acetyl-L-carnitine releases dopamine in rat corpus striatum: an in vivo microdialysis study. Eur J Pharmacol. 1992;218(1):117–21.</mixed-citation><mixed-citation xml:lang="ru">Harsing L.G., Sershen H., Toth E. et al. Acetyl-L-carnitine releases dopamine in rat corpus striatum: an in vivo microdialysis study. Eur J Pharmacol. 1992;218(1):117–21.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Hoefer M.E.,Voskanian S.J., Koob G.F., Pulvirenti L. Effects of terguride, ropinirole, and acetyl-L-carnitine on methamphetamine withdrawal in the rat. Pharmacol Biochem Behav 2006;83(3):403–9.</mixed-citation><mixed-citation xml:lang="ru">Hoefer M.E.,Voskanian S.J., Koob G.F., Pulvirenti L. Effects of terguride, ropinirole, and acetyl-L-carnitine on methamphetamine withdrawal in the rat. Pharmacol Biochem Behav 2006;83(3):403–9.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Jones L.L., McDonald D.A., Borum P.R. Acylcarnitines: role in brain. Prog Lipid Res 2010;49(1):61–75.</mixed-citation><mixed-citation xml:lang="ru">Jones L.L., McDonald D.A., Borum P.R. Acylcarnitines: role in brain. Prog Lipid Res 2010;49(1):61–75.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Madiraju P., Pande S.V., Prentki M., Madiraju S.R. Mitochondrial acetylcarnitine provides acetyl groups for nuclear histone acetylation. Epigenetics 2009;4: 399–403.</mixed-citation><mixed-citation xml:lang="ru">Madiraju P., Pande S.V., Prentki M., Madiraju S.R. Mitochondrial acetylcarnitine provides acetyl groups for nuclear histone acetylation. Epigenetics 2009;4: 399–403.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Masi F., Leggio B., Nanni G. et al. Effects of long-term acetyl-L-carnitine administration in Rats-II: Protection against the disrupting effect of stress on the acquisition of appetitive behavior. Neuropsychopharmacology 2003;28(4):683–93.</mixed-citation><mixed-citation xml:lang="ru">Masi F., Leggio B., Nanni G. et al. Effects of long-term acetyl-L-carnitine administration in Rats-II: Protection against the disrupting effect of stress on the acquisition of appetitive behavior. Neuropsychopharmacology 2003;28(4):683–93.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Pettegrew J.W., Levine J., McClure R.J. Acetyl-L-carnitine physical–chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression.Mol Psychiatry 2000;5(6):616–32.</mixed-citation><mixed-citation xml:lang="ru">Pettegrew J.W., Levine J., McClure R.J. Acetyl-L-carnitine physical–chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression.Mol Psychiatry 2000;5(6):616–32.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Pettegrew J.W., Levine J., Gershon S. et al. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord 2002;4(1):61–6.</mixed-citation><mixed-citation xml:lang="ru">Pettegrew J.W., Levine J., Gershon S. et al. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord 2002;4(1):61–6.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Pisano C., Pratesi G., Laccabue D. et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003;9(15):5756–67.</mixed-citation><mixed-citation xml:lang="ru">Pisano C., Pratesi G., Laccabue D. et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003;9(15):5756–67.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Pulvirenti G., Valerio C.,Spadaio F. et al. Acetylcarnitine reduces the immobility of rats in a despair test. Behav Neural Biol 1990;54(2):110–4.</mixed-citation><mixed-citation xml:lang="ru">Pulvirenti G., Valerio C.,Spadaio F. et al. Acetylcarnitine reduces the immobility of rats in a despair test. Behav Neural Biol 1990;54(2):110–4.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Ricciolini R., Scalibastri M., Kelleher J.K. Role of acetyl-L-carnitine in rat brain lipogenesis: implications for polyunsaturated fatty acid biosynthesis. J Neurochem 1998;71(6):2510–17.</mixed-citation><mixed-citation xml:lang="ru">Ricciolini R., Scalibastri M., Kelleher J.K. Role of acetyl-L-carnitine in rat brain lipogenesis: implications for polyunsaturated fatty acid biosynthesis. J Neurochem 1998;71(6):2510–17.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Rosca M.G., Lemieux H., Hoppel C.L. Mitochondria in the elderly: is acetylcarnitine a rejuvenator? Adv Drug Deliver Rev 2009;61(14);1332–42.</mixed-citation><mixed-citation xml:lang="ru">Rosca M.G., Lemieux H., Hoppel C.L. Mitochondria in the elderly: is acetylcarnitine a rejuvenator? Adv Drug Deliver Rev 2009;61(14);1332–42.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Taglialatela G., Navarra D., Cruciani R. et al. Acetyl-L-carnitine treatment increase nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. Exp Gerontol1994;29(1);55–66.</mixed-citation><mixed-citation xml:lang="ru">Taglialatela G., Navarra D., Cruciani R. et al. Acetyl-L-carnitine treatment increase nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. Exp Gerontol1994;29(1);55–66.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Tempesta E., Janiri L., Pirrongelli C. Stereospec ificeffects of acetylcarnitine on the spontaneous activity of brainstem neurones and their responses to acetylcholine andserotonin. Neuropharmacology 1985;24(1):43–50.</mixed-citation><mixed-citation xml:lang="ru">Tempesta E., Janiri L., Pirrongelli C. Stereospec ificeffects of acetylcarnitine on the spontaneous activity of brainstem neurones and their responses to acetylcholine andserotonin. Neuropharmacology 1985;24(1):43–50.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Tempesta E., Casella L., Pirrongelli C. et al. L-acetylcarnitine in depressed elderly subjects. Across-over study vs placebo. Drugs Exp Clin Res 1987;13(7):417–23.</mixed-citation><mixed-citation xml:lang="ru">Tempesta E., Casella L., Pirrongelli C. et al. L-acetylcarnitine in depressed elderly subjects. Across-over study vs placebo. Drugs Exp Clin Res 1987;13(7):417–23.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Tolu P., Masi F., Leggio B. et al. Effects of long-term acetyl-L-carnitine administration in rats. Increased dopamine output in mesocorticolimbic areas and protection toward acute stress exposure. Neuropsychopharmacology 2002;27(3):410–20.</mixed-citation><mixed-citation xml:lang="ru">Tolu P., Masi F., Leggio B. et al. Effects of long-term acetyl-L-carnitine administration in rats. Increased dopamine output in mesocorticolimbic areas and protection toward acute stress exposure. Neuropsychopharmacology 2002;27(3):410–20.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Valente M., Koverech A., Canonico P., Grilli M.G. Acetyl-L-carnitine, a new pharmacological modulator of adult hippocampal neurogenesis. Program no. 907.22PosterMM29. 2011 Neuroscience Meeting Planner. Washington, DC, Society for Neuroscience, 2011(online).</mixed-citation><mixed-citation xml:lang="ru">Valente M., Koverech A., Canonico P., Grilli M.G. Acetyl-L-carnitine, a new pharmacological modulator of adult hippocampal neurogenesis. Program no. 907.22PosterMM29. 2011 Neuroscience Meeting Planner. Washington, DC, Society for Neuroscience, 2011(online).</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Zanardi R., Smeraldi E. A double-blind, randomised, controlled clinical tria lof acetyl- L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharm 2006;16(4):281–7.</mixed-citation><mixed-citation xml:lang="ru">Zanardi R., Smeraldi E. A double-blind, randomised, controlled clinical tria lof acetyl- L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharm 2006;16(4):281–7.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
